A Study to Investigate Subcutaneous Isatuximab in Combination With Weekly Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma

The primary purpose of this study is to assess the efficacy (overall response rate) of subcutaneous (SC) via on body delivery system (SC-OBDS) isatuximab in combination with weekly carfilzomib and dexamethasone (Kd) in adult participants with RRMM having received 1 to 3 prior lines of therapy.

Trial Details

NCT ID
NCT06356571
Phase
PHASE2
Sponsor
Sanofi
Status
RECRUITING
Cancer Type
Relapsed/Refractory Multiple Myeloma
Interventions
  • Isatuximab SC-OBDS
  • Montelukast
  • Dexamethasone
  • Acetaminophen
  • Diphenhydramine
  • Methylprednisolone
Locations (sample)
  • Phoenix, Arizona, United States|33.44838,-112.07404
  • Los Angeles, California, United States|34.05223,-118.24368
  • West Hollywood, California, United States|34.09001,-118.36174
  • New Haven, Connecticut, United States|41.30815,-72.92816
  • Washington D.C., District of Columbia, United States|38.89511,-77.03637

Key Eligibility Criteria

  • Participants must have a documented diagnosis of MM.
  • Participants with measurable disease defined as at least one of the following:
  • Serum M-protein ≥0.5 g/dL measured using serum protein immunoelectrophoresis and/or
  • Urine M-protein ≥200 mg/24 hours measured using urine protein immunoelectrophoresis and/or

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Relapsed/Refractory Multiple Myeloma Trials on Trialify →